Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05247684

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer

Sponsor: Akeso

Conditions Resectable Non-small Cell Lung Cancer

Interventions AK112 Carboplatin Cisplatin Paclitaxel

Updated 5 times since 2022 Last updated: Mar 4, 2026 Started: Feb 20, 2022 Primary completion: Aug 18, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Resectable Non-small Cell Lung Cancer and is currently ongoing. Akeso leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Unknown → Active Not Recruiting
Feb 2025 — Mar 2026 [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Mar 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China